The development of dendritic cell vaccines involves several steps. Initially, dendritic cells are harvested from the patient’s blood. These cells are then cultured and exposed to antigens specific to the patient’s cancer cells. The loaded dendritic cells are subsequently matured and reintroduced into the patient’s body, where they present the antigens to T-cells, thereby eliciting a specific immune response against the cancer cells.
